BofA analyst Travis Steed lowered the firm’s price target on Medtronic (MDT) to $110 from $115 and keeps a Buy rating on the shares. Fiscal Q3 was roughly in line with expectations, FY26 growth and EPS guidance were reiterated and Medtronic continued to talk about accelerating revenue growth in FY27, notes the analyst after earnings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $100 from $103 at Baird
- Medtronic price target lowered to $100 from $105 at JPMorgan
- Medtronic resumed with an Outperform at Mizuho
- Medtronic: Solid Quarter but Limited Growth Visibility Justifies Hold Rating
- AtriCure price target lowered to $53 from $64 at Canaccord